Advertisement

Topics

Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

16:05 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- Cabozantinib Franchise Net Product Revenues of $51.9 million for the Fourth Quarter 2016, $135.4 million for the Full Year 2016 - - Total Revenues of $77.6 million for the Fourth Quarter 2016, $191.5 million for the F...

Other Sources for this Article

Exelixis, Inc.
Chris Senner, 650-837-7240
Chief Financial Officer
csenner@exelixis.com
or
Susan Hubbard, 650-837-8194
Executive Vice President, Public Affairs and Investor Relations
shubbard@exelixis.com

NEXT ARTICLE

More From BioPortfolio on "Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Thyroid Disorders
The thyroid is a butterfly-shaped gland in the neck, just above thecollarbone and is an endocrine gland that make hormones. These Thyroid hormones control the rate of many activities in the body, including how fast the body burns calories and how fast th...